{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:17:07Z","timestamp":1746591427613,"version":"3.37.3"},"reference-count":17,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2019,1,2]]},"DOI":"10.1080\/03007995.2018.1499507","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T10:32:45Z","timestamp":1531305165000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-8480","authenticated-orcid":false,"given":"Sigal","family":"Kaplan","sequence":"first","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Ehlken","sequence":"additional","affiliation":[{"name":"IQVIA (formerly IMS Health), Munich, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenia","family":"Hamann","sequence":"additional","affiliation":[{"name":"Ratiopharm GmbH (an affiliate of Teva Pharmaceuticals Europe BV), Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.726216"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04138.x"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802579769"},{"key":"CIT0004","unstructured":"European Medicines Agency. Notification of a referral under Article 107i of Directive 2001\/83\/EC. London, UK: EMA; February 28, 2013. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Flupirtine-containing_medicines\/Procedure_started\/WC500139756.pdf [Last accessed 28 September 2017]"},{"key":"CIT0005","unstructured":"European Medicines Agency: EMA\/404308\/2013. Assessment report for flupirtine containing medicinal products. London, UK: EMA; September 24, 2013; Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Flupirtine-containing_medicines\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500146103.pdf [Last accessed 24 September 2017]"},{"key":"CIT0006","unstructured":"Summary of Product Characteristics: Flupirtine. London, UK; 2015. Available at: http:\/\/mri.cts-mrp.eu\/download\/DE_H_3430_001_FinalSPC_2of2.pdf [Last accessed 28 September 2017]"},{"key":"CIT0007","unstructured":"European Medicines Agency. Withdrawal of pain medicine flupirtine endorsed. London, UK: EMA; March 23, 2018. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Flupirtine-31\/Position_provided_by_CMDh\/WC500248611.pdf [Last accessed 18 June 2018]"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.016"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.131"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01455-9"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.2165\/11599100-000000000-00000"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.308"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.242"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agt004"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2008.03.003"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.00133"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/bjaceaccp\/mki034"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2018.1499507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T15:11:22Z","timestamp":1599318682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2018.1499507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,2]]}},"alternative-id":["10.1080\/03007995.2018.1499507"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2018.1499507","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}